{"id":66697,"date":"2025-02-24T09:59:50","date_gmt":"2025-02-24T09:59:50","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2025\/02\/24\/key-cambridge-uk-vc-launches-126m-fund-to-stem-later-stage-flight\/"},"modified":"2025-02-24T10:02:08","modified_gmt":"2025-02-24T10:02:08","slug":"key-cambridge-uk-vc-launches-126m-fund-to-stem-later-stage-flight","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2025\/02\/24\/key-cambridge-uk-vc-launches-126m-fund-to-stem-later-stage-flight\/","title":{"rendered":"Key Cambridge, UK VC launches $126M fund to stem later stage flight"},"content":{"rendered":"

<\/a>\n<\/p>\n

\n

It\u2019s usually mentioned that the UK and Europe lack the massive stage of development funding for later-stage startups that the US has for its personal, and that is right.\u00a0In response to the European Funding Fund, there are no less than seven times more<\/a> large-size VC funds within the US than in Europe. So the looks of a brand new development fund within the UK is important.<\/p>\n

Cambridge\u00a0Innovation Capital<\/a> (CIC), which invests solely within the Cambridge\u00a0ecosystem in and across the well-known college, has launched a brand new \u00a3100 million ($126 million) \u2018Alternative Fund\u2019, primarily a development fund. CIC has $757 million invested in over 40 firms and has a privileged relationship with the College of\u00a0Cambridge.<\/p>\n

The fund is being anchored by Aviva Traders and British Affected person Capital and can spend money on growth-stage deep tech and life sciences firms.<\/p>\n

Two investments have already been made. Pragmatic Semiconductor<\/a> is a big chip designer and producer which has raised $389.3 million to this point, whereas Riverlane<\/a>, is a quantum computing error correction firm that has raised $120.7 million.\u00a0<\/p>\n

The brand new CIC fund will make investments as much as \u00a320 million ($25.2 million) per funding into the later-stage funding rounds of deep tech and life sciences firms. The hope, in fact, is to handle the UK\u2019s long-standing funding hole subject for later-stage startups, which tends to result in a drain of these firms in the direction of different international locations, often the US.\u00a0<\/p>\n

Partially, it\u2019s this subject that led the UK authorities to announce final month, its \u201cAI Motion Plan\u201d \u2014\u00a0a string of measures designed to develop the financial system utilizing AI, and included a pledge to construct Europe\u2019s \u201cSilicon Valley\u201d by super-charging the prevailing tech ecosystems across the well-known Oxford and Cambridge universities.\u00a0Plus, the \u201cGolden Triangle\u201d of London, Oxford, and Cambridge, comprising 5 main UK universities, may even be given larger hyperlinks, together with transportation, alongside a package deal of\u00a0 \u00a314 billion in funding.<\/p>\n

Andrew Williamson, Managing Associate at CIC, instructed TechCrunch over a name that CIC had historically invested in early-stage firms round\u00a0Cambridge, however there have been many who had been maturing into confirmed applied sciences.<\/p>\n

\u201cTraditionally, what we\u2019ve completed is when our firms get to Sequence C stage\u2026. we didn\u2019t have the capital in our core funds to make these [later stage] investments,\u201d he mentioned.\u00a0<\/p>\n

\u201cSo we used to supply them as co-investment to a few of our LPs. However not many establishments, notably monetary establishments, are actually set as much as make direct investments into firms. So the genesis of this fund was one they might take part in.\u201d<\/p>\n

He added that one of many key directives from the UK authorities to the British Enterprise Financial institution is to handle the later-stage hole in scale-up capital: \u201cSo this can be a good mission for what they\u2019re trying to do, to anchor new development funds like this. Within the case of Aviva, they\u2019re one of many signatories of the Mansion House Compact<\/a>. So that is round allocating a few of their pension fund capital into productive development property.\u201d<\/p>\n

Exits from CIC\u2019s portfolio embody the sale of gene remedy firm Gyroscope Therapeutics to Novartis for $1.5 billion, the $285 million acquisition of pet therapy developer PetMedix by Zoetis, the sale of liquid biopsy platform Inivata to NeoGenomics for $390 million, and the sale of sound recognition developer Audio Analytic.\u00a0<\/p>\n

Cambridge\u00a0is greatest identified for producing a number of vital firms together with ARM Holdings, Abcam, Darktrace, and Bicycle Therapeutics.<\/p>\n<\/div>\n